eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 15
 
Share:
Share:
more
 
 
Systematic review/Meta-analysis

A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations

Sorin Ursoniu, Amirhossein Sahebkar, Maria-Corina Serban, Iulia Pinzaru, Cristina Dehelean, Lavinia Noveanu, Jacek Rysz, Maciej Banach, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

Arch Med Sci 2019; 15, 1: 12–22
Online publish date: 2018/12/30
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Flaxseed (Linum usitatissiumum) is one of the most consistent sources in bioactive compounds such as polyunsaturated fatty acid, fibres, proteins, antioxidants, and lignans [1]. The translation of the Latin origin of the name, meaning “very useful”, is suggestive, considering the various products with biological effects that contain flaxseed and its fractions: flaxseed oil, whole seed, flaxseed meal, flaxseed mucilage and/or alcohol extracts, flaxseed hulls, ground whole seed, and flaxseed oleosomes [2]. Two major varieties of flaxseed products are available, but with different biological activity [1, 3]. Flaxseed contains one-third soluble and two-thirds insoluble fibres from a total of 35–45% of fibres. It also contains a high amount of α-linolenic acid, an essential fatty acid that cannot be synthesised by the human body [4]. Other biologically important compounds found in flaxseed products are linoleic acid, linolenic acid, alkaloids, cyclic peptides, lignans, polysaccharides, cyanogenic glycosides, and cadmium [2]. These compounds have remarkable antioxidant, hypotensive, anti-inflammatory, and hypoglycaemic activities [5, 6], being used for prevention of rheumatoid arthritis, cardiovascular (CV) diseases, and asthma [710].

A number of factors such as tumour necrosis factor (TNF), pro-inflammatory cytokines, and interleukins (IL) are responsible for increased levels of C-reactive protein (CRP), an important marker of systemic inflammation [11]. C-recative protein is also considered as a strong predictor of CV risk in comparison to several other inflammatory markers [12, 13]. Some studies suggest that this acute-phase protein marker, synthesised by the adipose tissue or by the liver, might be significantly influenced by the administration or consumption of different formulations of flaxseed, like flaxseed oil, flaxseed lignan, or flaxseed supplementation [14]. Therefore, the aim of the present study is to review available randomised clinical trials (RCTs) involving the use of different forms of flaxseed to evaluate their effectiveness on the CRP plasma concentration.

Material and methods

Search strategy

This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement [15]. EMBASE, ProQuest, CINAHL, and PUBMED databases were searched using the following search terms in titles and abstracts: (“linseed” OR “flax seed” OR “flaxseed” OR “linseed meal” OR “linum usitatissimum”) AND (“c reactive protein” OR “c reaction protein” OR “c-reactive protein” OR CRP OR “protein c reactive” OR “serum c reactive protein”). The wild-card term ‘‘*’’ was used to increase the sensitivity of the search strategy. The search was limited to studies in humans published in English. The literature was searched until 1st February 2016. Two reviewers (SU and M-CS) evaluated each article independently, carried out data extraction and quality assessment. Disagreements were resolved by discussion with a third party (MB).

Study selection

Original studies were included if they met the following inclusion criteria: (i) clinical trials with a case-control or cross-over design, (ii) investigation of the effect of flaxseed preparations on plasma CRP concentrations, (iii) providing baseline and end-trial plasma CRP concentrations in both flaxseed and control groups, and (iv) having a supplementation with flaxseed for at least 2 weeks.

Non-clinical studies, uncontrolled trials, and trials with insufficient data on CRP values in flaxseed and control groups were excluded from the meta-analysis.

Data extraction

Eligible studies were reviewed, and the following data were abstracted: 1) first author’s name; 2) year of publication; 3) country were the study was performed; 4) study design; 5) number of participants in the flaxseed and control groups; 6) intervention assigned to the control group; 7) type (lignan extract, ground powder, or oil) and dose of flaxseed supplement; 8) treatment duration; 9) age, gender, and body mass index (BMI) of study participants; 10) systolic and diastolic blood pressures; and 11) data regarding baseline and follow-up concentrations of CRP. Data extraction was performed independently by two reviewers; disagreements were resolved by a third reviewer.

Quality assessment

Assessment of risk of bias in the studies included in the analysis was performed systematically using the Cochrane quality assessment tool for RCTs [16]. The Cochrane tool has seven criteria for quality assessment: random sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other potential sources of bias. The risk of bias in each study was judged to be low, high, or unclear. Risk-of-bias assessment was performed independently by two reviewers; disagreements were resolved by a third reviewer.

Quantitative data synthesis

Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [17]. Net changes in measurements (change scores) were calculated as follows: measure at end of follow-up − measure at baseline. For single-arm, cross-over trials, the net change in plasma concentrations of CRP were calculated by subtracting the value after control intervention from that reported after treatment. All values were collated as mg/l. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root [(SDpre-treatment)2 + (SDpost-treatment)2 – (2 R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) equal to 0.5. If the outcome measures were reported in median and range (or 95% confidence interval (CI)), mean and standard SD values were estimated using the method described by Wan et al. [18] Where standard error of the mean (SEM) only was reported, the standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where n is the number of subjects.

Net changes in measurements (change scores) were calculated for parallel and cross-over trials, as follows: (measure at the end of follow-up in the treatment group – measure at baseline in the treatment group) – (measure at the end of follow-up in the control group – measure at baseline in the control group). A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and the characteristics of populations being studied [19]. Inter-study heterogeneity was assessed using Cochran Q test and I2 index. In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the leave-one-out method, i.e. iteratively removing one study each time and repeating the analysis.

Meta-regression

A weighted random-effects meta-regression using an unrestricted maximum likelihood model was performed to assess the association between the overall estimate of effect size with potential moderator variables, including dose and duration of supplementation with flaxseed.

Publication bias

Potential publication bias was explored using visual inspection of Begg’s funnel plot asymmetry, and Begg’s rank correlation and Egger’s weighted regression tests. The Duval and Tweedie “trim and fill” method was used to adjust the analysis for the effects of publication bias [20].

Results

Search results and trial flow

The initial screening comprised 587 full text articles, and we removed the articles with titles that were obviously irrelevant. Selected articles were hand searched to identify further relevant studies. Among 19 full text articles assessed for eligibility, two studies were excluded, being not controlled for flaxseed supplementation (Figure 1). After final assessment, 17 eligible trials achieved the inclusion criteria and were preferred for the final meta-analysis [7, 2136].

Figure 1

Flow chart of the number of studies identified and included into the meta-analysis

/f/fulltexts/AOMS/34567/AMS-15-34567-g001_min.jpg

Characteristics of included studies

In total, 1256 individuals were included to the meta-analysis, 639 participants were allocated to the flaxseed supplementation group and 617 to the control group. The number of participants in the analysed studies ranged from nine to 85 in the flaxseed group and from eight to 94 in the control group. The included studies were published between 2007 and 2015, and were conducted in the USA (n = 5), Brazil (n = 4), Canada (n = 3), China (n = 2), Greece, Denmark, and Iran. The following flaxseed supplementation was administered in the included trials: ground powder 13 g to 60 g/day (2.9 g to 10 g ALA/day), oil containing 1.022 g to 8 g ALA/day, and derived lignan complex 360 mg to 600 mg total SDG/day. Duration of flaxseed supplementation ranged between 2 weeks and 12 months. Ten trials were designed as a parallel group and seven as crossover studies. Table I shows the demographic characteristics and baseline parameters of the included studies. No adverse events related to the supplementation were reported.

Table I

Demographic characteristics and baseline parameters of the studies selected for analysis

ParameterStudy
Kontogianni et al. [21]Hutchins et al. [22]Zong et al. [23]Barre et al. [24]Lemos et al. [25]Rhee et al. [26]Faintuch et al. [27]Pan et al. [28]Dodin et al. [29]Bloedon et al. [30]Hallund et al. [31]Kaul et al. [32]Nelson et al. [33]Faintuch et al. [34]Cassani et al. [35]Demark- Wahnefried et al. [36]Khalatbari Soltani et al. [6]
Year20132013201320122012201120112009200820082008200820072007201520082013
LocationGreeceUSAChinaCanadaBrazilUSABrazilChinaCanadaUSADenmarkCanadaUSABrazilBrazilUSAIran
DesignRandomized, placebo-controlled crossover group trialRandomized, placebo-controlled crossover group trialRandomized single-blind placebo-controlled parallel group trialRandomized double-blind placebo-controlled crossover group trialRandomized double-blind, multicentre, placebo-controlled parallel group trialRandomized placebo-controlled crossover group trialRandomized double-blind placebo-controlled parallel- group trialRandomized double-blind crossover group trialRandomized double-blind placebo-controlled parallel group trialRandomized double-blind placebo-controlled parallel group trialRandomized double-blind placebo-controlled crossover group trialRandomized double-blind placebo-controlled parallel- group trialRandomized controlled parallel- group trialRandomized double-blind placebo-controlled crossover group trialRandomized single blind controlled parallel- group trialRandomized, multicentre, controlled parallel group trialRandomized, unblinded, controlled parallel group trial
Duration of trial6 weeks12 weeks12 weeks3 months4 months12 weeks12 weeks12 weeks12 months10 weeks6 weeks12 weeks8 weeks2 weeks42 days30 days8 weeks
Inclusion criteriaHealthy, normal weight males and females aged 18–35 yearsOverweight or obese men and postmenopausal women with pre- diabetes (impaired fasting glucose between 100 and 125 mg/dl)Individuals screened for metabolic syndrome following low-intensive lifestyle counsellingPatients 55 years of age or older, being postmenopausal (no menstruation for at least one year), not on insulin or changing exercise patterns, and healthy aside from type 2 diabetesPatients with terminal renal failure who were undergoing chronic haemodialysisObese glucose intolerant peopleActive males or females 18–65 years-old with BMI > 40 kg/m2, or > 35 kg/m2 with comorbidities, plus hsCRP > 5 mg/lType 2 diabetic patients 50–79 years of age (women postmenopausal for at least 1-year); LDL-C level > 2.9 mmol/l, and not using exogenous insulin for glycaemic controlWomen with at least 6 months of amenorrhea in the year before entry into the study and a normal mammogram in the past 2 yearsMen and post-menopausal women between the ages of 44 and 75 with hypercholesterolemiaHealthy postmenopausal women (defined as no menstrual period for > 24 month)Healthy male and female volunteersHealthy adult males and females abdominally overweight/obese (WC > 81 cm for females; WC > 94 cm for males) aged 20–68 yearsMales and females, 18–65 years old, BMI > 40 kg/m2 (or > 35 kg/m2 with comorbidities), non-hospitalized and receiving oral diet, with elevated C-reactive protein > 5 mg/lMales with at least three of the following cardiovascular risk factors: WC ≥ 90 cm; BMI ≥ 25 kg/m2; fasting TC ≥ 200 mg/dl, LDL-C ≥ 130 mg/dl, HDL-C < 40 mg/dl, TG ≥ 150 mg/dl; glycemia ≥ 100 mg/dl; SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm HgPatients with biopsy-confirmed prostatic carcinoma electing prostatectomy as their primary treatment and at least 21 days from scheduled surgeryAdult haemodialysis patients with dyslipidaemia (TG > 200 mg/dl and/or HDL-C < 40 mg/dl) aged between 23 and 77 years
Flaxseed formFlaxseed oilGround flaxseed powderGround flaxseed powderFlaxseed lignan complexFlaxseed oilGround flaxseed powderGround flaxseed powderFlaxseed lignan complexGround flaxseed powderGround flaxseed powderFlaxseed lignan complexFlaxseed oilFlaxseed oilGround flaxseed powderGround flaxseed powderGround flaxseed powderGround flaxseed powder
Flaxseed intervention15 ml/day containing 8 g of ALA13 g ground flaxseed containing 2.9 g of ALA30 g ground whole flaxseed providing 7 g ALA4 capsules – 600 mg total SDG/day2 g/day (2 capsules)40 g/day60 g/day containing 10 g ALA/day3 capsules – 360 mg total SDG/day40 g/day**40 g/day500 mg total SDG/day2 g/day (2 capsules) containing 1022 mg of ALA/day~11.6 g ALA/day30 g/day ~5 g of ALA60 g/day30 g/day40 g/day
26 g ground flaxseed containing 5.8 g of ALA30 g /day + low-fat diet
Participants:
 Case372583167091070853022222724144015
40
 Control9075894322224134115
Age [years]:
 Case25.6 ±5.958.6 ±6.348.9 ±8.166.2 ±1.7*55.7 ±13.054.7 ±6.647.8 ±8.0*62.9 ±7.554.0 ±4.056.8 ±7.361 ±734.70 ±1.69*37.74 ±11.840.8 ±11.640 ±960.2 ±7.054.0 ±4.0*
59.3 ±7.6
 Control48.7 ±7.958.3 ±14.850.7 ±6.4*55.4 ±4.557.0 ±8.032.93 ±1.99*39.42 ±10.4533 ±1058.2 ±6.854.5 ±4.0*
Male (%):
 Case21.6244.056.6NS55.744.4NS37.140.053.330.0NS21.017.7100.0100.066.6
100.0
 Control55.661.3NS0.046.87NS22.0100.0100.040.0
BMI [kg/m2]:
 Case21.9 ±2.530.4 ±5.325.1 ±2.331.2 ±2.2*25.1 ±3.4732.4 ±8.244.0 ±3.9*24.2 ±0.725.5 ±4.527.4 ±4.424.1 ±3.428.32 ±0.46*29.31 ±4.2747.1 ±7.232 ±328.5 ±3.925.5 ±2.0*
28.5 ±4.5
 Control22.0 ±2.625.5 ±2.424.2 ±4.2732.0 ±8.345.2 ±4.2*24.4 ±0.726.8 ±4.628.1 ±5.128.77 ±0.78*30.23 ±4.1447.2 ±7.232.1 ±2.828.8 ±4.027.0 ±1.0*
hs-CRP [mg/l]:
 Case0.45 ±0.473.0 ±3.21.01 (0.72–2.12)2.4 ±1.1*8.0 (2.3–16.8)3.6 ±1.712.9 ±7.2*1.67 ±0.19*2.02 ±2.601.36 (0.85–2.7)# 0.88 (0.63–2.05)# 319 ±65*2.40 ±2.3913.7 ±9.92.04 ±1.481.4 (1.0–2.7)##4.8 ±0.9*
3.2 ±2.81.2 (0.9–2.5)##
 Control0.66 ±1.062.9 ±3.01.12 (0.75–1.97)2.7 ±1.2*4.4 (2.3–7.6)3.6 ±1.710.5 ±5.5*1.42 ±0.19*2.18 ±2.291.06 (0.37–1.7)#0.80 (0.62–1.62)#314 ±69*2.79 ±1.8011.8 ±8.22.76 ±2.451.5 (1.1–2.2)## 4.0 ±0.6*
SBP [mm Hg]:
 CaseNSNS134.4 ±17.0133.6 ±4.8*NSNS126 ±10*124 ±3125.4 ±14.5NS124 ±13NSNSNS139 ±20.3NSNS
NSNS
 ControlNSNS134.5 ±14.5135.8 ±4.3*NSNS138 ±25*123 ±3122.4 ±15.5NSNSNSNS134 ±9.2NSNS
DBP [mm Hg]:
 CaseNSNS86.3 ±11.382.1 ±1.9*NSNS79 ±3*79.2 ±10.779.7 ±9.4NS75 ±8NSNSNS83 ±13.5NSNS
NSNS
 ControlNSNS85.9 ±8.884.5 ±2.2*NSNS92 ±16*79.3 ±10.377.7 ±9.4NSNSNSNS80 ±7.7NSNS

Values are expressed as mean ± SD or median (range)

* values are means ± SEM

** half of the daily amount was given as two slices of bread, which replaced the usual bread in the diet, and the other 20 g was provided as ground grains to add to cereal, juice, or yogurt, depending of the food preferences of the women

# median (IQR)

## median (95% CI).

BMI – body mass index, NS – not stated, SBP – systolic blood pressure, DBP – diastolic blood pressure, hs-CRP – high-sensitivity C-reactive protein, BMI – body mass index, CHD – coronary heart disease, ALA – α-linolenic acid, SDG – secoisolariciresinol diglucoside, WC – waist circumference, LDL-C – low-density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglycerides.

Risk of bias assessment

An unclear risk of bias with respect to sequence generation and allocation concealment was observed. Some trials were not blinded, but studies were low risk in terms of other sources of bias. The systematic assessment of bias in the included studies is shown in Table II.

Table II

Assessment of risk of bias in the included studies using Cochrane criteria

StudySequence generationAllocation concealmentBlinding of participants and personnelBlinding of outcome assessmentIncomplete outcome dataSelective outcome reportingOther potential threats to validity
Kontogianni et al. 2013 [21]UUHLLLL
Hutchins et al. 2013 [22]UUHLLLL
Zong et al. 2013 [23]UUHLLLL
Barre et al. 2012 [24]UULLLLL
Lemos et al. 2012 [25]UULLLLL
Rhee et al. 2011 [26]UUHLLLL
Faintuch et al. 2011 [27]UULLLLL
Pan et al. 2009 [28]LLLLLLL
Dodin et al. 2008 [29]LLLLLLL
Bloedon et al. 2008 [30]UULLLLL
Hallund et al. 2008 [31]UULLLLL
Kaul et al. 2008 [32]LLLLLLL
Nelson et al. 2007 [33]UUHHLLL
Faintuch et al. 2007 [34]UULLLLL
Cassani et al. 2015 [35]UUUULLL
Demark-Wahnefried et al. 2008 [36]LLHLLLL
Khalatbari Soltani et al. 2013 [6]UUHULLL

[i] L – low risk of bias, H – high risk of bias, U – unclear risk of bias.

Effect of flaxseed supplementation on plasma CRP concentrations

Meta-analysis of data from 17 trials did not suggest a significant change in plasma CRP concentrations following supplementation with flaxseed-containing products (WMD: –0.25 mg/l, 95% CI: –0.53, 0.02, p = 0.074; Q = 46.33, I 2 = 61.15%) (Figure 2 A). The effect size was robust in the leave-one-out sensitivity analysis (Figure 2 B). Subgroup analysis did not suggest any significant difference in terms of changing plasma CRP concentrations among different types of flaxseed supplements used in the included studies, i.e. flaxseed oil (WMD: –0.67 mg/l, 95% CI: –2.00, 0.65, p = 0.32; Q = 28.63, I 2 = 82.54%) (Figure 3 A), lignan extract (WMD: –0.32 mg/l, 95% CI: –0.71, 0.06, p = 0.103; Q = 0.02, I 2 = 0%) (Figure 3 B), and ground powder (WMD: –0.18 mg/l, 95% CI: –0.42, 0.06, p = 0.142; Q = 13.44, I 2 = 33.06%) (Figure 3 C).

Figure 2

Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of flaxseed supplementation on plasma C-reactive protein concentrations. Lower plot shows leave-one-out sensitivity analysis

/f/fulltexts/AOMS/34567/AMS-15-34567-g002_min.jpg
Figure 3

Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of flaxseed oil (A), lignan extract (B), and ground powder (C) on plasma C-reactive protein concentrations

/f/fulltexts/AOMS/34567/AMS-15-34567-g003_min.jpg

Meta-regression

Meta-regression analysis was conducted to evaluate the association between changes in plasma CRP concentrations and potential confounders, including duration of supplementation with flaxseed and changes in plasma LDL-C concentrations. No significant association was found between changes in plasma CRP levels with either supplementation duration (slope: –0.001; 95% CI: –0.02 to 0.02; p = 0.928) or plasma LDL-C changes (slope: 0.05; 95% CI: –0.01 to 0.12; p = 0.095) (Figure 4).

Figure 4

Meta-regression plots of the association between mean changes in plasma C-reactive protein concentrations with duration of supplementation and changes in plasma LDL-C concentrations

/f/fulltexts/AOMS/34567/AMS-15-34567-g004_min.jpg

Publication bias

Visual inspection of funnel plots suggested an asymmetry in the meta-analyses of flaxseed’s effects on plasma CRP concentrations. Using a “trim and fill” method six potentially missing studies were imputed on the right side of the funnel plot (Figure 5). However, the corrected effect size remained non-significant after imputation (WMD: –0.10 mg/l, 95% CI: –0.42, 0.22). The results of Egger’s linear regression (intercept = –0.86, standard error = 0.35; 95% CI: –1.59, –0.12, t = 2.44, df = 18, two-tailed p = 0.025) but not Begg’s rank correlation (Kendall’s τ with continuity correction = –0.19, z = 1.20, two-tailed p = 0.223) suggested publication bias in the meta-analysis.

Figure 5

Funnel plot displaying publication bias in the studies reporting the impact of flaxseed supplementation on plasma C-reactive protein concentrations

/f/fulltexts/AOMS/34567/AMS-15-34567-g005_min.jpg

Discussion

This meta-analysis did not suggest a significant change in plasma CRP concentrations following supplementation with flaxseed-containing products. Subgroup analysis also did not suggest any significant difference in terms of changing plasma CRP concentrations among different types of flaxseed supplements used in the included studies, i.e. flaxseed oil, lignan extract, and ground powder.

A reason for these effects could be that flaxseed oil does not contain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fatty acids, while the presence of α-linolenic acid may not be sufficient for such beneficial effects [8]. Despite the fact that α-linolenic acid undergoes conversions to longer-chain n-3 polyunsaturated fatty acids or essential fatty acids such as EPA, docosapentaenoic acid (DPA), and DHA, the exact percentage of these conversions in the cells, plasma, and tissues are still not known [37]. The α-linolenic acid contained in flaxseed products was shown to inhibit the metabolisation of arachidonic acid to more inflammatory cytokines [38]. Furthermore, different factors such as smoking, gender, and high intake of long-chain n-3 polyunsaturated fatty acids were shown to affect the metabolic capacity of α-linolenic acid conversions [39, 40]. It has been shown that younger women have a greater capacity of conversion of α-linolenic acid to essential fatty acids than older women and men, due to having a hormonal profile more sensitive to diet [41]. This capacity of conversion of α-linolenic acid to essential fatty acids is even greater during the period of pregnancy and lactation.

Another fact that may account for these results is that less than 10% of dietary α-linolenic acid is incorporated in the plasma phospholipid pool [42]. Moreover, the beneficial effects of α-linolenic acid derived from plant sources, which is less effective than omega-3 obtained from animal sources, might also influence the results on flaxseed supplements and products on plasma CRP levels.

Lignans, the precursors of enterodiol and enterolactone, are also important compounds found in flaxseed products converted by the microbial flora in the colon [8, 43]. The administration of the principal lignan of flaxseed, secoisolariciresinol diglucoside and its primary metabolites: secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL), on male Wistar rats, showed short half-lives, a large volume of distribution, and a high systemic clearance [44]. These pharmacokinetics properties of lignans might also explain the lack of effects of flaxseed products on plasma CRP levels. Another potential reason may lie in the fact that the effects of fatty acids on inflammatory cells are modulated by changes in fatty acid composition of cell membranes, causing lipid raft production, changes of membrane fluidity, and modifications of gene expression and of the pattern of peptide and lipid mediator production [4550].

The present meta-analysis has some limitations. There were only a few eligible RCTs, and most of them had a small number of participants with suitable short time of supplementation, and they were heterogeneous regarding the characteristics of patients and study design. Many characteristics that vary within studies, such as the type of flaxseed products, the background of the patients included, the control groups, or the quality of the studies, could have been factors of between-study heterogeneity. Our results showed that the significance of estimated pooled effect size was not biased by any single study.

In conclusion, this meta-analysis of available randomised controlled trials does not suggest any significant benefit of flaxseed product supplementation in decreasing plasma CRP concentrations. Larger, well-designed studies with higher doses and longer follow-up should be performed to validate the current results.

Acknowledgments

The meta-analysis was prepared within the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group (www.lbpmcgroup.umed.pl).

Conflict of interest

The authors declare no conflict of interest.

References

1 

Goyal A, Sharma V, Upadhyay N, Gill S, Sihag M , authors. Flax and flaxseed oil: an ancient medicine and modern functional food. J Food Sci Technol. 2014. 51:p. 1633–53

2 

Shim YY, Gui B, Arnison PG, Wang Y, Reaney MJT , authors. Flaxseed (Linum usitatissimum L.) bioactive compounds and peptide nomenclature: a review. Trends Food Sci Technol. 2014. 38:p. 5–20

3 

Zuravski L, Coelho RP, Duarte JA, et al. , authors. Protective role of golden flaxseed (Linum usitatissimum L.) against oxidative damage in lipids and proteins of healthy volunteers. J Biosci Med. 2015. 3:p. 45–53

4 

Edel AL, Rodriguez-Leyva D, Maddaford TG, et al. , authors. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease. J Nutrition. 2015. 145:p. 749–57

5 

Caligiuri SP, Edel AL, Aliani M, Pierce GN , authors. Flaxseed for hypertension: implications for blood pressure regulation. Curr Hypertens Rep. 2014. 16:p. 499.

6 

Khalatbari Soltani S, Jamaluddin R, Tabibi H, et al. , authors. Effects of flaxseed consumption on systemic inflammation and serum lipid profile in hemodialysis patients with lipid abnormalities. Hemodial Int. 2013. 17:p. 275–81

7 

Kajla P, Sharma A, Sood DR , authors. Flaxseed – a potential functional food source. J Food Sci Technol. 2015. 52:p. 1857–71

8 

Sahebkar A, Serban C, Ursoniu S, Banach M , authors. Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition. 2016. 32:p. 33–40

9 

Serban C, Sahebkar A, Antal D, Ursoniu S, Banach M , authors. Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutrition. 2015. 31:p. 1061–71

10 

Serban MC, Sahebkar A, Dragan S, et al. , authors. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. Clin Nutr. 2016. 35:p. 842–51

11 

Prasad K , author. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006. 24:p. 33–50

12 

Koenig W, Sund M, Fröhlich M, et al. , authors. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999. 99:p. 237–42

13 

Ridker PM, Hennekens CH, Buring JE, Rifai N , authors. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000. 342:p. 836–43

14 

Rhee Y, Brunt A , authors. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J. 2011. 10:p. 44.

15 

Moher D, Liberati A, Tetzlaff J, Altman DG , authors; PRISMA Group , author. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009. 339:p. b2535.

16 

Green S , author. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. 2011

17 

Borenstein M, et al. , authors. Comprehensive meta-analysis version 2. 2005. Englewood, NJ: Biostat; p. 104

18 

Wan X, Wang W, Liu J, Tong T , authors. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014. 14:p. 135.

19 

Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F , authors. Methods for meta-analysis in medical research. 2000. New York: John Wiley;

20 

Duval S, Tweedie R , authors. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000. 56:p. 455–63

21 

Kontogianni MD, Vlassopoulos A, Gatzieva A, et al. , authors. Flaxseed oil does not affect inflammatory markers and lipid profile compared to olive oil, in young, healthy, normal weight adults. Metabolism. 2013. 62:p. 686–93

22 

Hutchins AM, Brown BD, Cunnane SC, Domitrovich SG, Adams ER, Bobowiec CE , authors. Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: a randomized study. Nutr Res. 2013. 33:p. 367–75

23 

Zong G, Demark-Wahnefried W, Wu H, Lin X , authors. Effects of flaxseed supplementation on erythrocyte fatty acids and multiple cardiometabolic biomarkers among Chinese with risk factors of metabolic syndrome. Eur J Nutr. 2013. 52:p. 1547–51

24 

Barre DE, Mizier-Barre KA, Stelmach E, et al. , authors. Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis – an invitation to further investigation into polypharmacy reduction. J Nutr Metabol. 2012. 2012:p. 585170.

25 

Lemos JR, Alencastro MG, Konrath AV, Cargnin M, Manfro RC , authors. Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients. Nutr Res. 2012. 32:p. 921–7

26 

Rhee Y, Brunt A , authors. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J. 2011. 10:p. 44.

27 

Faintuch J, Bortolotto LA, Marques PC, Faintuch JJ, França JI, Cecconello I , authors. Systemic inflammation and carotid diameter in obese patients: pilot comparative study with flaxseed powder and cassava powder. Nutr Hosp. 2011. 26:p. 208–13

28 

Pan A, Demark-Wahnefried W, Ye X, et al. , authors. Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients. Br J Nutr. 2009. 101:p. 1145–9

29 

Dodin S, Cunnane SC, Mâsse B, et al. , authors. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutrition. 2008. 24:p. 23–30

30 

Bloedon LT, Balikai S, Chittams J, et al. , authors. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr. 2008. 27:p. 65–74

31 

Hallund J, Tetens I, Bügel S, Tholstrup T, Bruun JM , authors. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovasc Dis. 2008. 18:p. 497–502

32 

Kaul N, Kreml R, Austria JA, et al. , authors. A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. J Am Coll Nutr. 2008. 27:p. 51–8

33 

Nelson TL, Stevens JR, Hickey MS , authors. Inflammatory markers are not altered by an eight week dietary alpha-linolenic acid intervention in healthy abdominally obese adult males and females. Cytokine. 2007. 38:p. 101–6

34 

Faintuch J, Horie LM, Barbeiro HV, et al. , authors. Systemic inflammation in morbidly obese subjects: response to oral supplementation with alpha-linolenic acid. Obes Surg. 2007. 17:p. 341–7

35 

Cassani RS, Fassini PG, Silvah JH, Lima CM, Marchini JS , authors. Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study. Nutr J. 2015. 14:p. 1–8

36 

Demark-Wahnefried W, et al. , authors. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prevent. 2008. 17:p. 3577–87

37 

Burdge GC, Calder PC , authors. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev. 2005. 45:p. 581–97

38 

James MJ, Gibson RA, Cleland LG , authors. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000. 71:p. 343s–8s

39 

Childs CE, Kew S, Finnegan YE, et al. , authors. Increased dietary alpha-linolenic acid has sex-specific effects upon eicosapentaenoic acid status in humans: re-examination of data from a randomised, placebo-controlled, parallel study. Nutr J. 2014. 13:p. 113.

40 

Marangoni F, Colombo C, De Angelis L, et al. , authors. Cigarette smoke negatively and dose-dependently affects the biosynthetic pathway of the n-3 polyunsaturated fatty acid series in human mammary epithelial cells. Lipids. 2004. 39:p. 633–7

41 

Burdge GC, Calder PC , authors. Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev. 2006. 19:p. 26–52

42 

Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP , authors. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr. 2006. 84:p. 44–53

43 

Ursoniu S, Sahebkar A, Andrica F, et al. , authors. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial. Clin Nutr. 2016. 35:p. 615–25

44 

Mukker JK, Singh RS, Muir AD, Krol ES, Alcorn J , authors. Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats. Br J Nutr. 2015. 113:p. 749–57

45 

Calder PC , author. Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol. 2011. 668 Suppl 1:p. S50–8

46 

Sahebkar A, Serban MC, Gluba-Brzózka A, et al. , authors. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016. 32:p. 1179–92

47 

Banach M, Patti AM, Giglio RV, et al. , authors; International Lipid Expert Panel (ILEP) , author. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018. 72:p. 96–118

48 

Patti AM, Al-Rasadi K, Giglio RV, et al. , authors. Natural approaches in metabolic syndrome management. Arch Med Sci. 2018. 14:p. 422–41

49 

Cicero AFG, Colletti A, Bajraktari G, et al. , authors. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017. 13:p. 965–1005

50 

Soran H, Adam S, Mohammad JB, et al. , authors. Hypercholesterolaemia – practical information for non-specialists. Arch Med Sci. 2018. 14:p. 1–21

Copyright: © 2018 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe